Skip to main content

Table 4 Clinical and histological features of sixty patients subjected to neoadjuvant chemotherapy with docetaxel plus epirubicin. Patients were divided according to clinical response as objective response (OR) and no response (NR) groups.

From: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

  OR (n) NR (n) P Test
Age     
Median (range) 51,5 (35 – 67) 47,5 (29 – 68) 0.3 Student t
≤ 45 anos 12 7   
>45 anos 35 7 0.1 Fisher
Menopausal Status     
Post 24 8   
Pre 22 6 0.9 x2
CT cycle (range) 3 (2 – 5) 3 (2 – 4) 0.4 Mann-Whitney
CS     
IIA 8 4   
IIB 15 4   
IIIA 5 2   
IIIB 14 4   
IIIC 3 0 0.78 x2
Grade     
I 10 6   
II 27 5   
III 8 3 0.2 x2
ER     
Positive 32 12   
Negative 12 2 0.48 Fisher
PR     
Positive 20 7   
Negative 25 7 0.76 Fisher
ER/PR     
Positive 16 7   
Negative 22 7 0.75 Fisher
P53     
Positive 16 2   
Negative 30 12 0.19 Fisher
P21     
Positive 15 5   
Negative 31 9 1 Fisher
HER-2     
Positive 10 1   
Negative 36 13 0.43 Fisher
  1. OR = objective response; NR = no response; n = number of patients; CT = chemotherapy; CS = clinical staging; Grade = histological grade (Bloom-Richardson); ER = estrogen receptor; PR = progesterone receptor.